title: Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes.
abstract: BACKGROUND
  The purpose of this study was to determine if there is any additional benefit from FSH priming in addition to hCG priming on in-vitro maturation (IVM) programmes.
  
  
  METHODS
  Sixty women with polycystic ovary syndrome (PCOS) who underwent 68 IVM cycles were randomized by computer-generated numbers to receive FSH stimulation or not. Thirty-five cycles were pretreated with 75 IU rFSH for 6 days, and 33 cycles were not. Every cycle was given hCG 10,000 IU 36 h before oocyte retrieval. Immature oocytes were matured in vitro and fertilized by ICSI, and the resulting embryos were replaced on day 2 or 3.
  
  
  RESULTS
  A total of 1528 immature oocytes were recovered. The overall maturation and fertilization rates were 74.2 and 72.8% respectively. After embryo transfer, 23 pregnancies resulted (33.8%). The oocyte numbers and endometrial thickness were similar between FSH-primed and non-FSH-primed groups. Serum estradiol level on the day of hCG injection was significantly higher in the FSH-primed group than in the non-FSH-primed group (377.2 pmol/l versus 143.8 pmol/l, P=0.001). The maturation rate, fertilization rate and pregnancy rate were 76.5, 75.8 and 31.4% respectively for FSH-primed group, and 71.9, 69.5 and 36.4% respectively for non-FSH-primed group (all not significant).
  
  
  CONCLUSIONS
  IVM is a feasible treatment for women with PCOS. FSH priming has no additional beneficial effect on IVM.
authors.affiliation: Department of Obstetrics and Gynecology and Department of Pediatrics, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
authors.forename: Yu-Hung
authors.initials: YH
authors.lastname: Lin
authors.forename: Jiann-Loung
authors.initials: JL
authors.lastname: Hwang
authors.forename: Lee-Wen
authors.initials: LW
authors.lastname: Huang
authors.forename: Shu-Chi
authors.initials: SC
authors.lastname: Mu
authors.forename: Kok-Min
authors.initials: KM
authors.lastname: Seow
authors.forename: Jesse
authors.initials: J
authors.lastname: Chung
authors.forename: Bih-Chwen
authors.initials: BC
authors.lastname: Hsieh
authors.forename: Shih-Chia
authors.initials: SC
authors.lastname: Huang
authors.forename: Chin-Yu
authors.initials: CY
authors.lastname: Chen
authors.forename: Pei-Hsin
authors.initials: PH
authors.lastname: Chen
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D005260:Female; D005307:Fertilization in Vitro; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage*; D006801:Humans; D066298:In Vitro Techniques; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D009865:Oocytes / Q000187:drug effects* / Q000254:growth & development*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000628:therapy; D011247:Pregnancy; D027724:Reproductive Techniques, Assisted
chemical_list: D006063:Chorionic Gonadotropin; D043373:Follicle Stimulating Hormone, Human